SEA’S ONLY VACCINES & BIOLOGICS PLATFORM FROM DISCOVERY TO DELIVERY

14 - 15 October 2026 | Jakarta, Indonesia

Building on the momentum of its successful edition, 8th Vaccine World Asia – Southeast Asia 2026 returns as the region’s most influential gathering for vaccine leaders, with a dedicated spotlight on Indonesia and the broader SEA vaccine ecosystem. As SEA experiences rising vaccine demand driven by persistent public health challenges—including dengue, hepatitis, tuberculosis, influenza, and emerging infectious diseases—governments are boosting investments in immunization programs, manufacturing capabilities, and resilient supply chains. Indonesia, one of the region’s largest and fastest-growing vaccine markets, continues to scale its national immunization efforts, strengthen domestic production, and advance collaborations to achieve vaccine self-sufficiency.

At the same time, SEA faces ongoing barriers such as fragmented regulatory pathways, supply chain bottlenecks, cold-chain limitations, decentralized healthcare infrastructure, and pockets of vaccine hesitancy—especially across rural and remote areas. Rapidly evolving technologies such as mRNA, recombinant platforms, viral vectors, thermostable formulations, and improved delivery systems are reshaping the region’s vaccine landscape, offering new pathways to bridge immunization gaps and enhance outbreak preparedness.

8th Vaccine World Asia Congress 2026 – Southeast Asia emerges as the go-to strategic event for vaccine leaders across SEA. The congress will spotlight critical pathways for unlocking regional growth, including strengthening domestic manufacturing, improving cross-border regulatory harmonization, expanding vaccination coverage, accelerating innovation in universal and next-generation vaccines, and modernizing production through digitalized, cost-efficient processes. By convening leading policymakers, manufacturers, researchers, global health organizations, and technology partners, the event serves as a catalyst for reshaping the future of vaccine development and immunization delivery throughout SEA.

Biologics World Southeast Asia is a premier regional platform dedicated to advancing the development, manufacturing, and commercialisation of therapeutic biologics across ASEAN. The conference convenes senior leaders from biopharma, biotech, CDMOs, academia, regulators, investors, and technology providers to address the strategic opportunities shaping Southeast Asia’s biologics landscape.

As demand for monoclonal antibodies, biosimilars, and next-generation biologics continues to rise across the region, Southeast Asia is emerging as a critical hub for clinical development, manufacturing expansion, and healthcare innovation. Governments across Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the wider ASEAN region are accelerating investments into life sciences infrastructure, regulatory strengthening, and local production capabilities to enhance healthcare resilience and reduce reliance on imports.

The conference explores the full therapeutic biologics value chain — from R&D and translational science to bioprocessing, manufacturing scale-up, CDMO partnerships, and market access. Through strategic discussions and real-world case studies, the programme highlights regional capabilities, investment priorities, and collaboration opportunities driving the growth of biologics adoption in Southeast Asia.

Biologics World Southeast Asia is co-located with the Vaccine World Southeast Asia Congress, creating a unified platform that brings together stakeholders across the broader biopharmaceutical ecosystem. While the Vaccine Congress focuses on infectious diseases, immunisation strategies, and vaccine innovation, Biologics World Southeast Asia maintains a dedicated emphasis on therapeutic biologics, including monoclonal antibodies, biosimilars, antibody-drug conjugates (ADCs), and protein therapeutics.

This co-located format enables cross-industry exchange while preserving distinct scientific and commercial discussions, fostering stronger partnerships across research, manufacturing, and healthcare delivery.

By convening global and regional decision-makers under one platform, Biologics World Southeast Asia aims to support Southeast Asia’s transformation into a competitive biologics hub — strengthening manufacturing capabilities, improving patient access to advanced therapies, and positioning ASEAN as a key contributor within the global biologics value chain.